Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 71335-1558

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 71335-1558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351558)

Label for Rabeprazole Sodium delayed-release 20 mg tablets by Bryant Ranch Prepack. The label compares this product to Aciphex 20 mg tablet by Aurobindo Pharma USA, Inc. It includes storage instructions at room temperature (20°-25°C) and safety warning to keep drugs out of children's reach. The label shows the lot number 1523487 and NDC 71335-1558-2 for 90 tablets.*

FDA Label Image

Rabeprazole Fig1

A line graph showing mean heartburn scores over 28 study days comparing placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. The x-axis represents study days, including days before and after treatment start. The y-axis shows mean heartburn scores ranging from none to very severe. The graph illustrates score trends for each group over time.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Fig2)

A line graph showing mean heartburn scores over study days for placebo and two doses of Rabeprazole Sodium (10 mg and 20 mg). The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (None) to 4 (Very Severe). Three lines compare heartburn severity among placebo (n=68), Rabeprazole 10 mg (n=64), and Rabeprazole 20 mg (n=67) groups.*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Fig3)

A line graph comparing mean heartburn scores over study days between placebo and Rabeprazole Sodium 20 mg groups. The x-axis shows study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The graph shows scores decreasing after study day 0 with Rabeprazole Sodium 20 mg slightly lower than placebo.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Fig4)

A line graph comparing mean heartburn scores over 28 days between a placebo group (n=58) and a Rabeprazole Sodium 20 mg group (n=59). Scores range from 0 (none) to 4 (very severe), showing a decrease in heartburn severity in both groups after day 0, with lower scores in the Rabeprazole group throughout the study period.*

FDA Label Image

Chemical Structure (Rabeprazole Str)

Chemical structure of Rabeprazole Sodium, illustrating its molecular framework including sodium atom, sulfur dioxide group, and methoxy-substituted aromatic rings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.